Novo Nordisk A/S NVO:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 12:40 PM EDT

123.83

-0.08 (-0.06%)

Volume

1,843,116

52 week range

75.56 - 138.28

Open123.07
Day High124.07
Day Low121.79
Prev Close123.90
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23

Key Stats

Market Cap558.451B
Shares Out4.51B
10 Day Average Volume3.49M
Dividend1.37
Dividend Yield1.10%
Beta0.44
YTD % Change19.87

KEY STATS

Open123.07
Day High124.07
Day Low121.79
Prev Close123.90
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23
Market Cap558.451B
Shares Out4.51B
10 Day Average Volume3.49M
Dividend1.37
Dividend Yield1.10%
Beta0.44
YTD % Change19.87

RATIOS/PROFITABILITY

EPS (TTM)2.76
P/E (TTM)44.91
Fwd P/E (NTM)0.78
EBITDA (TTM)15.646B
ROE (TTM)88.07%
Revenue (TTM)33.078B
Gross Margin (TTM)84.60%
Net Margin (TTM)36.03%
Debt To Equity (MRQ)25.34%

EVENTS

Earnings Date05/02/2024(est)
Ex Div Date03/22/2024
Div Amount0.9293
Split Date-
Split Factor-

Latest On Novo Nordisk A/S

These are the top 5 companies to work for in India, according to LinkedIn14 Hours AgoCNBC.com
A top Nvidia shareholder reveals his trigger for selling growth stocksApril 14, 2024CNBC.com
Eli Lilly's top drug last year is softening. But it may not matter for the stockApril 12, 2024CNBC.com
EU probe of weight loss, diabetes drugs finds no link to suicidal thoughtsApril 12, 2024CNBC.com
10 things to watch in the stock market Friday, including Wells Fargo earningsApril 12, 2024CNBC.com

Content From Our Affiliates

LLY, NVO: Obesity Drugs May Help with Parkinson’sApril 12, 2024TipRanks
Buy Rating for Novo Nordisk: Strong Growth Potential Driven by Strategic Partnerships and Innovative PipelineApril 12, 2024TipRanks
Novo Nordisk Launches Major Share BuybackApril 8, 2024TipRanks
Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-CapApril 5, 2024TipRanks
Novo Nordisk Initiates Multi-Billion Share BuybackApril 2, 2024TipRanks

Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral...

Henrik Poulsen

Vice Chairman of the Board

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Maziar Doustdar

Executive Vice President - International Operations

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Douglas Langa

Executive Vice President, North America Operations

Address

Novo Alle 1

Bagsvaerd

2880

Denmark

https://www.novonordisk.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
JNJ Johnson & Johnson	143.99	-3.60	-2.44%
CAH Cardinal Health Inc	107.44	+0.41	+0.38%
RDY Dr Reddy's Laboratories Ltd	71.58	+0.46	+0.65%
MRK Merck & Co Inc	125.61	-0.58	-0.46%
ABBV AbbVie Inc	163.41	+1.74	+1.07%